The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models
Igor A Korostil, Suzanne M Garland, Matthew G Law, David G Regan
BMC Infectious Diseases | BMC | Published : 2013
Awarded by Australian Research Council
Awarded by National Health and Medical Research Council
The authors of this manuscript do not perceive any direct conflict of interest in relation to the research described. However, in the interest of full disclosure, we declare the following:The research described in this manuscript was funded by an Australian Research Council Linkage Project (LP0883831). CSL Limited, the distributor of Gardasil (R) in Australia and New Zealand, is a Partner Organization on this project.Igor Korostil's salary is funded by the above mentioned grant (LP0883831). Professor Suzanne Garland has received advisory board fees and grant support from CSL Ltd and GlaxoSmithKline (GSK), and lecture fees from Merck, GSK and Sanofi Pasteur; in addition, she has received funding through her institution to conduct HPV vaccine studies for Merck and GSK. She is a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV.This work was supported by an Australian Research Council Linkage Project [LP0883831] and a National Health and Medical Research Council Program Grant . The Kirby Institute receives funding from the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. The Kirby Institute is affiliated with the Faculty of Medicine, University of New South Wales.